Discussions on Recent Data and Best Practices for Managed Care in the Treatment of nAMD and DME

This activity was originally broadcast in conjunction with the 2023 AMCP Annual Meeting.

Program Description

Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are 2 leading causes of vision loss among adults worldwide, affecting over 40 million people globally. Intravitreal anti-vascular endothelial growth factor (VEGF) therapies have been the gold standard for the treatment of nAMD and DME to reduce the rates of vision loss through the prevention of the growth of new blood vessels. However, adverse effects and the burden of frequent injections due to undesirable treatment durability often lead to poorer real-world outcomes compared with what is seen in clinical trials. Managed care professionals must be able to identify gaps in patients’ treatment and consider evidence supporting recent advancements in therapies in order to optimize patient outcomes while providing cost-effective care. This activity will review recent data on the advances in nAMD and DME treatment in addition to best practices in applying the clinical data to managed care considerations. This expert panel discussion will highlight the burden of the diseases and treatments and discuss a patient’s journey through various treatment strategies utilizing patient cases.

Target audience: Managed care pharmacists

Type of activity: Application
Release date: April 7, 2023
Expiration date: April 7, 2024

Time to complete activity: 1.5 hours

Learner level: Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Expose the disease burden and limitations of anti-vascular endothelial growth factor (VEGF) treatment in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
• Explore the recent updates on the efficacy and safety of available treatment approaches for nAMD and DME to close the gaps in care.
• Apply the best practices for managed care professionals to incorporate the latest data and advances in treatment to improve outcomes for patients with nAMD and DME.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-23-129-H01-P. The activity is available for CE credit through April 7, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Joshua Mali, MD, has the following financial relationships with commercial interests to disclose:

• Grant/Research Support: Regeneron, Chengdu Kanghong Biotechnology, Santen, Allergen, Alimera Sciences, Notal Vision
• Consultant: Regeneron, Genentech, Novartis, Sun Pharmaceuticals, Kaia Pharmaceuticals, Macular Degeneration Association, Allergan, Alimera Sciences, Notal Vision, Eyepoint Pharmaceuticals
• Speaker’s Bureau: Genentech, Novartis, Sun Pharmaceuticals, Kaia Pharmaceuticals, Macular Degeneration Association, Alimera Sciences, Notal Vision

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Steven Kheloussi, PharmD, MBA

Susan Trieu, PharmD

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Karleen Rush, PharmD; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms